Advertisement
Perspectives

Simplifying the Energy Balance Message for Breast Cancer Prevention

Carol J. Fabian
DOI: 10.1158/1940-6207.CAPR-12-0088 Published April 2012

Abstract

Simple prevention messages based on understandable biologic principles are likely to be adopted. The long-held premise that postmenopausal obesity elevates, but premenopausal obesity reduces, risk for breast cancer is confusing to the public. Furthermore, decades of positive energy balance may be difficult to suddenly reverse at the time of the menopause. In this issue (beginning on page 583), Cecchini et al. suggest that obesity may also be a risk factor for pre-menopausal women 35 and older who have additional risk factors for breast cancer. Although the relative impact of dysregulated energy metabolism depends on many factors including age, hormonal milieu, and competing risk factors, as well as how it is measured, avoiding weight gain after age 30 is increasingly being recognized as a simple way to reduce risk of breast cancer. Cancer Prev Res; 5(4); 511–4. ©2012 AACR.

Perspective on Cecchini et al., p. 583

In this issue of the journal, Cecchini and colleagues report that overweight and obese premenopausal women 35 and older from the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 trial had a greater chance of developing breast cancer than did their more slender counterparts (1). However, overweight and obese postmenopausal women who were in P-1 or the NSABP Study of Tamoxifen and Raloxifene (STAR) were reported as not having a significantly increased risk of breast cancer. These results fly in the face of everything we thought we knew. How can they be explained?

Eight-seven percent of the group of postmenopausal women enrolled in P-1 or STAR were randomized to receive the selective estrogen receptor modulator (SERM) tamoxifen or raloxifene, and for these women, no increase in breast cancer risk was observed with increasing category of body mass index (BMI). This finding is not surprising, as the moderately elevated estrogen levels often observed in overweight or obese postmenopausal women could be expected to be easily overcome by SERMs, and the majority of obesity-related tumors in postmenopausal women are hormone receptor positive (2). Furthermore, both tamoxifen and raloxifene reduce the insulin-like growth factor 1 (IGF-1):IGF-binding protein 3 (IGFBP3) molar ratio and increase sex hormone–binding globulin, favorably modulating these additional risk biomarkers for breast cancer (3–5). Thus, it seems logical that the excess risk normally associated with postmenopausal obesity should be largely abrogated by SERM treatment in the NSABP trials.

But what about the lack of significant effect of BMI on risk for breast cancer in postmenopausal women in P-1 randomized to placebo? Although the P value for trend with increasing BMI was nonsignificant for the entire group of postmenopausal women, overweight women with a BMI of 25 to 30 kg/m2 exhibited hazard ratio (HR) of 1.77 with a 95% confidence interval (CI) of 1.05 to 2.97, consistent with an effect for this subgroup. Lack of significance for increasing BMI for the postmenopausal placebo group as a whole could potentially be explained by the relatively small numbers per subgroup and prior use of hormone replacement therapy (HRT) by approximately 50% of postmenopausal women in P-1 and STAR. Current and prior HRT use have been reported to attenuate the excess risk normally observed in postmenopausal obese women; current use perhaps more so than past use (6–8). It is not clear why hormone replacement in postmenopausal women reduces the impact of obesity on risk of breast cancer. One potential explanation is that the risk of exogenous hormones is offset by estrogen's favorable effects on adiponectin, proinflammatory cytokines, and insulin resistance in obese women (9, 10).

BMI was positively associated with risk in premenopausal women, who were all age 35 and older. Although the authors indicated no significant interaction between BMI and treatment, HRs for premenopausal obese women randomized to tamoxifen were elevated at 2.33 (95% CI, 1.10–4.90) compared with women with a normal BMI; and P for trend overall was significant at 0.02. Thus, the risk of breast cancer appeared higher for obese compared with normal weight women randomized to tamoxifen. The HR for obese premenopausal women randomized to placebo was elevated at 1.41, but the 95% CI included one. Why would tamoxifen be less effective in obese premenopausal women than in their normal weight counterparts? Tamoxifen reduces insulin sensitivity and increases estradiol by 3- to 10-fold in premenopausal women (11–13), which may offset the favorable small decreases in IGF-1 (3, 14). It is conceivable that tamoxifen- and obesity-induced hyperinsulinemia, added to the substantial tamoxifen-induced elevations in estrogen levels, could explain a reduced effectiveness.

Thus, the obesity–breast cancer findings from the 2 NSABP prevention trials reported by Cecchini and colleagues likely are not at odds with what has been reported in the literature, but rather are the result of the complex interplay of energy balance, endogenous hormones and growth factors, prior exogenous hormones, current SERM use, and competing major risk factors.

Large cohort studies have suggested that adult weight gain and postmenopausal obesity as measured by BMI increase the risk of postmenopausal breast cancer in women not using HRT (6, 8, 15–19). This appears to be the case both for average-to-moderate risk and for very high–risk populations (20). Adult weight gain after age 18, particularly after age 30, may be a more important predictor than is BMI for postmenopausal breast cancer (8, 21). A weight gain of 10 kg has been reported to be associated with a 30% increase, a 20 to 30 kg gain with a doubling, and a 50-kg gain with a 3-fold increase in the risk for breast cancer in postmenopausal women who do not use HRT (15–17). Other studies report that the pattern of fat deposition may be more predictive for breast cancer risk than is BMI or weight gain alone (22–24).

The observation that obesity as measured by BMI does not universally correlate with postmenopausal breast cancer (25) suggests that BMI and adult weight gain are surrogate markers for the impact of a dysregulated energy metabolism on breast epithelium. In postmenopausal women, the likely molecular effectors of risk from obesity and accompanying dysregulated energy metabolism include elevated levels of free estrogen resulting from increased levels of proinflammatory cytokines and enhanced aromatase activity and/or from lowered sex hormone–binding globulin resulting from insulin resistance (26, 27).

Conversely, obesity in otherwise average-risk premenopausal women has been previously reported to decrease the risk of premenopausal breast cancer by 40% to 70%, with obesity at age 18 being strongly protective (28). Anovulatory cycles in young obese premenopausal women, with reductions in mid-cycle progesterone and free estradiol, have been offered as explanations for this phenomenon (29–31). The observation that the protective effect of obesity on breast cancer risk is limited to women who were obese before age 35 (32) supports this hypothesis.

Hormonal alterations are likely only part of the complex formula of how energy balance relates to breast cancer risk (33). Obesity at a very young age may be protective in part due to lower systemic levels of IGF-1 in later adulthood (34). Hyperglycemia and insulin resistance are likely factors for obesity-related elevated risk (35–39). It is increasingly recognized that the proinflammatory state and insulin resistance often associated with obesity may result in nonhormonal direct paracrine effects on breast epithelium through the activation of pathways important in breast cancer promotion and progression such as NF-κB, phosphoinositide 3-kinase (PI3K), and Akt/mTOR (26, 40–44). The ability to produce and/or secrete the protective adipokine adiponectin and the amount of adiponectin relative to leptin (45–48) are likely to modulate the effects of positive energy balance on these pathways. Systemic levels of adiponectin, which are lowered in insulin resistance and obesity, are inversely related to risk of breast cancer and breast cancer progression (49–52). However, obese women with high levels of adiponectin seem to be protected both from several metabolic consequences of obesity (53) and from breast cancer (54, 55).

Although there is clear evidence that adult weight gain increases risk, the evidence is less clear that, once obese, weight loss abrogates that risk. Available studies suggest that reduction in risk is likely only if women achieve at least a 5% to 10% weight loss maintained over several years (56). A 10% or greater loss is also needed to increase adiponectin and improve other inflammatory markers in obese women (57). Unfortunately, only 20% of women are able to achieve such a loss and maintain it for 2 or more years (21, 58).

Endocrine therapies, including tamoxifen, raloxifene, and aromatase inhibitors, have been shown in randomized trials to reduce risk of breast cancer by 40% to 60% (59). Survival is not improved when any of these agents is given as primary prevention to a general high-risk cohort irrespective of weight (59, 60). Uptake of endocrine therapies for primary prevention is low (61, 62).

Women at increased risk for breast cancer because of family history or a precancerous biopsy are often eager for nonprescription, nonendocrine interventions to reduce their risk. A growing body of evidence, including data from the NSABP trials, suggests that adult weight gain and obesity, particularly after the ages of 30 to 35 years old, are risk factors for breast cancer regardless of menopause status. This conclusion simplifies the message about energy balance and breast cancer risk. Avoidance of adult weight gain through diet and exercise should be a standard component of breast cancer risk counseling (63).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: C.J. Fabian

Writing, review, and/or revision of the manuscript: C.J. Fabian

  • Received February 21, 2012.
  • Revision received February 24, 2012.
  • Accepted February 28, 2012.

References

  1. 1.↵
    1. Cecchini R,
    2. Costantino JP,
    3. Cauley JA,
    4. Cronin WM,
    5. Wickerham DL,
    6. Land SR,
    7. et al.
    Body mass index and the risk for developing invasive breast cancer among high risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prev Res 2012;5:583–92.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Vrieling A,
    2. Buck K,
    3. Kaaks R,
    4. Chang-Claude J
    . Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res Treat 2010;123:641–9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Decensi A,
    2. Robertson C,
    3. Guerrieri-Gonzaga A,
    4. Serrano D,
    5. Cazzaniga M,
    6. Mora S,
    7. et al.
    Randomized double-blind 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 2009;27:3749–56.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Bonanni B,
    2. Serrano D,
    3. Gandini S,
    4. Guerrieri-Gonzaga A,
    5. Johansson H,
    6. Macis D,
    7. et al.
    Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia. Clin Cancer Res 2009;15:7053–60.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Gibney J,
    2. Johannsson G,
    3. Leung KC,
    4. Ho KK
    . Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women. J Clin Endocrinol Metab 2005;90:3897–903.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Morimoto LM,
    2. White E,
    3. Chen Z,
    4. Chlebowski RT,
    5. Hays J,
    6. Kuller L,
    7. et al.
    Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002;13:741–51.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Rose DP,
    2. Vona-Davis L
    . Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 2010;66:33–8.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. White KK,
    2. Park SY,
    3. Kolonel LN,
    4. Henderson BE,
    5. Wilkens LR
    . Body size and breast cancer risk: The multiethnic cohort. Int J Cancer. 2011 Nov 28.[Epub ahead of print].
  9. 9.↵
    1. Kuhl H
    . Breast cancer risk in the WHI study: the problem of obesity. Maturitas 2005;51:83–97.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Christodoulakos GE,
    2. Lambrinoudaki IV,
    3. Creatsa MG,
    4. Economou EV,
    5. Siasou Z,
    6. Panoulis CP,
    7. et al.
    Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women. Climacteric 2008;11:155–65.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Johansson H,
    2. Gandini S,
    3. Guerrieri-Gonzaga A,
    4. Iodice S,
    5. Ruscica M,
    6. Bonanni B,
    7. et al.
    Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res 2008;68:9512–8.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Cohen I,
    2. Figer A,
    3. Tepper R,
    4. Shapira J,
    5. Altaras MM,
    6. Yigael D,
    7. et al.
    Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. Gynecol Oncol 1999;72:202–7.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Manni A,
    2. Pearson OH
    . Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 1980;64:779–85.
    OpenUrlPubMed
  14. 14.↵
    1. Friedl A,
    2. Jordan VC,
    3. Pollak M
    . Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 1993;29A:1368–72.
    OpenUrlPubMed
  15. 15.↵
    1. Huang Z,
    2. Hankinson SE,
    3. Colditz GA,
    4. Stampfer MJ,
    5. Hunter DJ,
    6. Manson JE,
    7. et al.
    Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278:1407–11.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Lahmann PH,
    2. Schulz M,
    3. Hoffmann K,
    4. Boeing H,
    5. Tjønneland A,
    6. Olsen A,
    7. et al.
    Long-term weight change and breast cancer risk: the European prospective investigation into cancer and nutrition (EPIC). Br J Cancer 2005;93:582–9.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Harvie M,
    2. Howell A,
    3. Vierkant RA,
    4. Kumar N,
    5. Cerhan JR,
    6. Kelemen LE,
    7. et al.
    Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2005;14:656–61.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Ahn J,
    2. Schatzkin A,
    3. Lacey JV Jr.,
    4. Albanes D,
    5. Ballard-Barbash R,
    6. Adams KF,
    7. et al.
    Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 2007;167:2091–102.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Canchola AJ,
    2. Anton-Culver H,
    3. Bernstein L,
    4. Clarke CA,
    5. Henderson K,
    6. Ma H,
    7. et al.
    Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer Causes Control. 2012 Jan 28. [Epub ahead of print].
  20. 20.↵
    1. Manders P,
    2. Pijpe A,
    3. Hooning MJ,
    4. Kluijt I,
    5. Vasen HF,
    6. Hoogerbrugge N,
    7. et al.
    Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat 2011;126:193–202.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Michels KB,
    2. Terry KL,
    3. Eliassen AH,
    4. Hankinson SE,
    5. Willett WC
    . Adult weight change and incidence of premenopausal breast cancer. Int J Cancer 2012;130:902–9.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Harvie M,
    2. Howell A
    . Energy balance adiposity and breast cancer—energy restriction strategies for breast cancerprevention. Obes Rev 2006;7:33–47.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Kaaks R,
    2. Van Noord PA,
    3. Den Tonkelaar I,
    4. Peeters PH,
    5. Riboli E,
    6. Grobbee DE
    . Breast cancer incidence in relation to height, weight and body fat distribution in the Dutch “DOM” cohort. Int J Cancer 1998;76:647–51.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Huang Z,
    2. Willett WC,
    3. Colditz GA,
    4. Hunter DJ,
    5. Manson JE,
    6. Rosner B,
    7. et al.
    Waist circumference, waist: hip ratio, and risk of breast cancer in the Nurses' Health Study. Am J Epidemiol 1999;150:1316–24.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Eichholzer M,
    2. Schmid SM,
    3. Bovey F,
    4. Jordan P,
    5. Rohrmann S,
    6. Huang DJ,
    7. et al.
    Impact of overweight and obesity on postmenopausal breast cancer: analysis of 20-year data from Switzerland. Arch Gynecol Obstet 2012;285:797–803.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Morris PG,
    2. Hudis CA,
    3. Giri D,
    4. Morrow M,
    5. Falcone DJ,
    6. Zhou XK,
    7. et al.
    Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 2011;4:1021–9.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Key TJ,
    2. Appleby PN,
    3. Reeves GK,
    4. Roddam AW,
    5. Helzlsouer KJ,
    6. Alberg AJ,
    7. et al.
    Endogenous Hormones and Breast Cancer Collaborative Group. Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 2011;105:709–22.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Baer HJ,
    2. Tworoger SS,
    3. Hankinson SE,
    4. Willett WC
    . Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol 2010;171:1183–94.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Sherman BM,
    2. Korenman SG
    . Measurement of serum LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the inadequate luteal phase. J Clin Endocrinol Metab 1974;39:145–9.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Zain MM,
    2. Norman RJ
    . Impact of obesity on female fertility and fertility treatment. Womens Health (Lond Engl) 2008;4:183–94.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Terry KL,
    2. Willett WC,
    3. Rich-Edwards JW,
    4. Michels KB
    . A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med 2006;166:2484–9.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Peacock SL,
    2. White E,
    3. Daling JR,
    4. Voigt LF,
    5. Malone KE
    . Relation between obesity and breast cancer in young women. Am J Epidemiol 1999;149:339–46.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Pichard C,
    2. Plu-Bureau G,
    3. Neves-E Castro M,
    4. Gompel A
    . Insulin resistance, obesity and breast cancer risk. Maturitas 2008;60:19–30.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Poole EM,
    2. Tworoger SS,
    3. Hankinson SE,
    4. Schernhammer ES,
    5. Pollak MN,
    6. Baer HJ
    . Body size in early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3. Am J Epidemiol 2011;174:642–51.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Schernhammer ES,
    2. Holly JM,
    3. Pollak MN,
    4. Hankinson SE
    . Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:699–704.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Rollison DE,
    2. Newschaffer CJ,
    3. Tao Y,
    4. Pollak M,
    5. Helzlsouer KJ
    . Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. Int J Cancer 2006;118:1279–84.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Sieri S,
    2. Pala V,
    3. Brighenti F,
    4. Pellegrini N,
    5. Muti P,
    6. Micheli A,
    7. et al.
    Dietary glycemic index, glycemic load, and the risk of breast cancer in an Italian prospective cohort study. Am J Clin Nutr 2007;86:1160–6.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Del Giudice ME,
    2. Fantus IG,
    3. Ezzat S,
    4. McKeown-Eyssen G,
    5. Page D,
    6. Goodwin PJ
    . Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998;47:111–20.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Lipscombe LL,
    2. Goodwin PJ,
    3. Zinman B,
    4. McLaughlin JR,
    5. Hux JE
    . Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res Treat 2006;98:349–56.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Chen J
    . Multiple signal pathways in obesity-associated cancer. Obes Rev 2011;12:1063–70.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. De Angel RE,
    2. Conti CJ,
    3. Wheatley KE,
    4. Brenner AJ,
    5. Otto G,
    6. Degraffenried LA,
    7. et al.
    The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. Mol Carcinog. 2012 Jan 30. [Epub ahead of print].
  42. 42.↵
    1. Crowe FL,
    2. Key TJ,
    3. Allen NE,
    4. Appleby PN,
    5. Overvad K,
    6. Grønbæk H,
    7. et al.
    A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Hum Biol 2011;38:194–202.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Nogueira LM,
    2. Dunlap SM,
    3. Ford NA,
    4. Hursting SD
    . Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Endocr Relat Cancer 2012;19:57–68.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Subbaramaiah K,
    2. Howe LR,
    3. Bhardwaj P,
    4. Du B,
    5. Gravaghi C,
    6. Yantiss RK,
    7. et al.
    Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 2011;4:329–46.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Cleary MP,
    2. Ray A,
    3. Rogozina OP,
    4. Dogan S,
    5. Grossmann ME
    . Targeting the adiponectin:leptin ratio for postmenopausal breast cancer prevention. Front Biosci (Schol Ed) 2009;1:329–57.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Jardé T,
    2. Caldefie-Chézet F,
    3. Goncalves-Mendes N,
    4. Mishellany F,
    5. Buechler C,
    6. Penault-Llorca F,
    7. et al.
    Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer 2009;16:1197–210.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Grossmann ME,
    2. Ray A,
    3. Dogan S,
    4. Mizuno NK,
    5. Cleary MP
    . Balance of adiponectin and leptin modulates breast cancer cell growth. Cell Res 2008;18:1154–6.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Grossmann ME,
    2. Ray A,
    3. Nkhata KJ,
    4. Malakhov DA,
    5. Rogozina OP,
    6. Dogan S,
    7. et al.
    Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev 2010;29:641–53.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Vona-Davis L,
    2. Rose DP
    . Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007;14:189–206.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Macis D,
    2. Gandini S,
    3. Guerrieri-Gonzaga A,
    4. Johansson H,
    5. Magni P,
    6. Ruscica M,
    7. et al.
    Prognostic effect of circulating adiponectin in a randomized 2 × 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer. J Clin Oncol 2012;30:151–7.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Bredella MA,
    2. Torriani M,
    3. Ghomi RH,
    4. Thomas BJ,
    5. Brick DJ,
    6. Gerweck AV,
    7. et al.
    Adiponectin is inversely associated with intramyocellular and intrahepatic lipids in obese premenopausal women. Obesity 2011;19:911–6.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Turer AT,
    2. Khera A,
    3. Ayers CR,
    4. Turer CB,
    5. Grundy SM,
    6. Vega GL,
    7. et al.
    Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia 2011;54:2515–24.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Aguilar-Salinas CA,
    2. García EG,
    3. Robles L,
    4. Riaño D,
    5. Ruiz-Gomez DG,
    6. García-Ulloa AC,
    7. et al.
    High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 2008;93:4075–9.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Duggan C,
    2. Irwin ML,
    3. Xiao L,
    4. Henderson KD,
    5. Smith AW,
    6. Baumgartner RN,
    7. et al.
    Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 2011;29:32–9.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Körner A,
    2. Pazaitou-Panayiotou K,
    3. Kelesidis T,
    4. Kelesidis I,
    5. Williams CJ,
    6. Kaprara A,
    7. et al.
    Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007;92:1041–8.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Eliassen AH,
    2. Colditz GA,
    3. Rosner B,
    4. Willett WC,
    5. Hankinson SE
    . Adult weight change and risk of postmenopausal breast cancer. JAMA 2006;296:193–201.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Madsen EL,
    2. Rissanen A,
    3. Bruun JM,
    4. Skogstrand K,
    5. Tonstad S,
    6. Hougaard DM,
    7. et al.
    Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008;158:179–87.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Teras LR,
    2. Goodman M,
    3. Patel AV,
    4. Diver WR,
    5. Flanders WD,
    6. Feigelson HS
    . Weight loss and postmenopausal breast cancer in a prospective cohort of overweight and obese US women. Cancer Causes Control 2011;22:573–9.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Goss PE,
    2. Ingle JN,
    3. Alés-Martínez JE,
    4. Cheung AM,
    5. Chlebowski RT,
    6. Wactawski-Wende J,
    7. et al.
    Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381–91.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Cuzick J,
    2. Forbes JF,
    3. Sestak I,
    4. Cawthorn S,
    5. Hamed H,
    6. Holli K,
    7. et al.
    Long-term results of tamoxifen prophylaxis for breast cancer–96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272–82.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Port ER,
    2. Montgomery LL,
    3. Heerdt AS,
    4. Borgen PI
    . Patient reluctance toward tamoxifen use for breast cancer primary prevention.Ann Surg Oncol 2001;8:580–5.
    OpenUrlPubMed
  62. 62.↵
    1. Land SR,
    2. Cronin WM,
    3. Wickerham DL,
    4. Costantino JP,
    5. Christian NJ,
    6. Klein WM,
    7. et al.
    Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res 2011;4:1393–400.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Kushi LH,
    2. Doyle C,
    3. McCullough M,
    4. Rock CL,
    5. Demark-Wahnefried W,
    6. Bandera EV,
    7. et al.
    American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2012;62:30–67.
    OpenUrlCrossRefPubMed
Back to top
Cancer Prevention Research: 5 (4)
April 2012
Volume 5, Issue 4

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
Simplifying the Energy Balance Message for Breast Cancer Prevention
Carol J. Fabian
Cancer Prev Res April 1 2012 (5) (4) 511-514; DOI: 10.1158/1940-6207.CAPR-12-0088
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement